1245899-93-7Relevant academic research and scientific papers
5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert- Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643) - A potent FLAP inhibitor suitable for topical administration
Stock, Nicholas,Baccei, Christopher,Bain, Gretchen,Chapman, Charles,Correa, Lucia,Darlington, Janice,King, Christopher,Lee, Catherine,Lorrain, Daniel S.,Prodanovich, Pat,Santini, Angelina,Schaab, Kevin,Evans, Jilly F.,Hutchinson, John H.,Prasit, Peppi
scheme or table, p. 4598 - 4601 (2010/10/02)
AM643 (compound 6, 3-{3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)- benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid) was identified as a potential candidate for formulation as a topical agent for the treatment of skin disorders involving leukotriene production. Dermal application of 6 using a prototypical vehicle in a murine ear arachidonic acid model showed significant reduction in the concentrations of leukotrienes in mouse skin with concomitant reduction in ear swelling.
